BMYBristol-Myers SquibbRunning, no new patients
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Melanoma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 100 (final count)
- Started
- Nov 6, 2023
- Main results expected
- Apr 10, 2025
- Fully finished
- Dec 21, 2026
- Results posted
- Apr 9, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose
Measured over: Cycle 4 Day 1 (each cycle consist of 4 weeks)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06101134 · record last updated 2026-09-14 · checked 2026-11-09 15:47 UTC